Central Nervous System Involvement in Extranodal NK/T-Cell Lymphoma: Risk Stratification, Prophylaxis, and Management

Extranodal NK/T-cell lymphoma (ENKTL) is an Epstein–Barr virus (EBV)-driven malignancy concentrated in East Asia and Latin America. Central nervous system (CNS) involvement occurs in 1.3–5.8% of largely unselected cohorts and carries a median survival of a few months. It has been reviewed only within broader T-cell scopes, never with ENKTL as the subject, although ENKTL is the only subtype in that lineage with its own validated CNS relapse model. Cohorts of more than 4500 patients support four observations. Incidence estimates are barely comparable because the CNS endpoint differs in almost every study; the reported range probably understates the true burden through incomplete cerebrospinal fluid (CSF) ascertainment. Meanwhile, two competing-risk analyses indicate that truncation of the observation window conceals little. Risk is concentrated in a definable subgroup: CNS-PINK, a two-point index for NK-cell lymphoma, separates a high-risk group with 2-year CNS relapse of 13.9–22.8% from a low-risk group at 4.1–4.5%, yet it assigns no patient with localized disease to that group, and a pan-T/NK model (CITI) did not select ENKTL as a risk histology. Prophylaxis evidence is internally inconsistent: the only positive signal, systemic intermediate-dose methotrexate, came from one training cohort and did not reach significance on validation, against uniformly conservative guidelines. Diagnosis is shifting from cytology toward CSF flow cytometry and circulating tumor DNA. Prophylaxis can neither be recommended nor withheld on current evidence; for each of the three decisions, we set out what the literature reaches and how far.

Authors

Institutions

Publication Details

Journal
Cancers
Published
2026-11-19
DOI
https://doi.org/10.3390/cancers18223706
Primary Topic
CNS Lymphoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Central Nervous System Involvement in Extranodal NK/T-Cell Lymphoma: Risk Stratification, Prophylaxis, and Management

Fang Zhu, Jingkai Song, Xinxiu Liu, Liling Zhang et al.
Cancers
CNS Lymphoma Diagnosis and Treatment
article

Central Nervous System Involvement in Extranodal NK/T-Cell Lymphoma: Risk Stratification, Prophylaxis, and Management

Fang Zhu, Jingkai Song, Xinxiu Liu, Liling Zhang, Tao Liu
article en

Abstract

Extranodal NK/T-cell lymphoma (ENKTL) is an Epstein–Barr virus (EBV)-driven malignancy concentrated in East Asia and Latin America. Central nervous system (CNS) involvement occurs in 1.3–5.8% of largely unselected cohorts and carries a median survival of a few months. It has been reviewed only within broader T-cell scopes, never with ENKTL as the subject, although ENKTL is the only subtype in that lineage with its own validated CNS relapse model. Cohorts of more than 4500 patients support four observations. Incidence estimates are barely comparable because the CNS endpoint differs in almost every study; the reported range probably understates the true burden through incomplete cerebrospinal fluid (CSF) ascertainment. Meanwhile, two competing-risk analyses indicate that truncation of the observation window conceals little. Risk is concentrated in a definable subgroup: CNS-PINK, a two-point index for NK-cell lymphoma, separates a high-risk group with 2-year CNS relapse of 13.9–22.8% from a low-risk group at 4.1–4.5%, yet it assigns no patient with localized disease to that group, and a pan-T/NK model (CITI) did not select ENKTL as a risk histology. Prophylaxis evidence is internally inconsistent: the only positive signal, systemic intermediate-dose methotrexate, came from one training cohort and did not reach significance on validation, against uniformly conservative guidelines. Diagnosis is shifting from cytology toward CSF flow cytometry and circulating tumor DNA. Prophylaxis can neither be recommended nor withheld on current evidence; for each of the three decisions, we set out what the literature reaches and how far.

CancersVol. 18(22)
Wuhan Union Hospital (CN), Huazhong University of Science and Technology (CN)
CNS Lymphoma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon